Women's International Pharmacy: Best Alternatives for Each Use Case

What Women's International Pharmacy Actually Does

WIP compounds custom hormone formulations (creams, capsules, troches, suppositories, and sublingual preparations) from bulk pharmaceutical-grade ingredients. Their catalog covers estradiol, estriol, progesterone, testosterone, DHEA, and thyroid combinations. Orders require a valid prescription from an outside provider.

The pharmacy holds PCAB accreditation, which means independent audits of sterility, potency, and beyond-use dating. PCAB standards exceed state board minimums, though they do not equal FDA current Good Manufacturing Practice (cGMP) requirements applied to commercial drug manufacturers [1]. The 2012 New England Compounding Center meningitis outbreak (N=753 cases, 64 deaths) prompted Congress to pass the Drug Quality and Security Act of 2013, which created a voluntary federal registration pathway (503B outsourcing facilities) with stricter FDA oversight [2]. WIP operates as a traditional 503A pharmacy, meaning it compounds on a patient-specific basis under state board jurisdiction rather than FDA facility inspection.

For patients already established with WIP, the question is rarely whether the pharmacy is "legit." It is whether a better-matched option exists for their specific clinical scenario.

When an FDA-Approved Product May Be the Stronger Choice

The Endocrine Society's 2015 scientific statement on compounded bioidentical hormones concluded that FDA-approved bioidentical formulations should be used preferentially when available because they offer validated pharmacokinetics and consistent batch potency [3]. The North American Menopause Society (NAMS) 2022 position statement echoed this guidance, noting that custom compounding is appropriate when FDA-approved options cannot meet a patient's dosing or delivery needs [4].

FDA-approved bioidentical options include:

• Estradiol patches (Climara, Vivelle-Dot, generic): 0.025 to 0.1 mg/day transdermal delivery with established pharmacokinetic profiles [5]
• Oral micronized progesterone (Prometrium, generic): the PEPI trial (N=875) confirmed endometrial protection equivalent to medroxyprogesterone acetate with a more favorable lipid profile [6]
• Estradiol vaginal inserts (Imvexxy, Vagifem): local therapy for genitourinary syndrome of menopause
• Testosterone (off-label): no FDA-approved female testosterone product exists in the US, making this a legitimate compounding indication

If your hormone regimen can be replicated with commercially available products, switching may reduce cost variability and eliminate potency concerns. A 2006 FDA survey of compounded hormone products found that 34% failed potency testing [7]. PCAB-accredited pharmacies like WIP likely perform better than that average, but published potency data from specific 503A pharmacies remains unavailable.

Alternative Compounding Pharmacies: Head-to-Head

Several other compounding pharmacies serve the same BHRT market. Selection criteria should include accreditation status, formulary breadth, turnaround time, and whether the pharmacy offers prescriber coordination.

Belmar Pharmacy (Lakewood, CO): PCAB-accredited, broad hormone formulary, integrates with a network of prescribers. Ships nationwide. Pricing comparable to WIP ($35, $100/month for standard formulations). Offers real-time prescription tracking.

College Pharmacy (Colorado Springs, CO): PCAB-accredited, specializes in complex multi-ingredient compounds. Known for thyroid and adrenal formulations. Slightly higher pricing tier due to specialty focus.

Help Pharmacy (Houston, TX): Registered 503B outsourcing facility under direct FDA oversight. Produces both patient-specific and office-use compounds. The 503B designation means batch testing and FDA inspection, offering a regulatory middle ground between traditional compounding and commercial manufacturing [8].

University Compounding Pharmacy (San Diego, CA): PCAB-accredited, strong hormone therapy and pain management formulary. Pharmacist consultations available.

The primary differentiator between WIP and these alternatives is not quality (all hold equivalent accreditation) but rather workflow integration, formulary specialization, and geographic shipping logistics.

Telehealth Platforms That Bundle Prescribing and Compounding

A newer category bypasses the traditional model (find a prescriber, then find a pharmacy) by combining both under one platform. These services pair licensed clinicians with in-house or contracted compounding pharmacies.

Advantages: single point of contact, streamlined refills, lab monitoring coordination, and often transparent flat-rate pricing.

Limitations: less prescriber choice, potentially narrower formulary, and the prescribing clinician may not be a hormone specialist with decades of experience.

Examples in this space include platforms offering compounded testosterone, progesterone, and estradiol with integrated lab panels and follow-up visits. Monthly costs typically range from $99, $249 depending on the hormone combination and visit frequency.

For women specifically seeking BHRT, the trade-off is between WIP's pure compounding expertise (you bring your own prescriber) and telehealth platforms' convenience (everything in one workflow). Neither model is inherently superior. The right answer depends on whether you already have a knowledgeable prescriber.

The Progesterone Question: Compounded vs. Commercial

Oral micronized progesterone (Prometrium) is FDA-approved and available as a generic. The REPLENISH trial (N=1,845) confirmed that combining estradiol with progesterone maintained endometrial safety over 12 months [9]. Generic micronized progesterone costs $15, $40/month at retail pharmacies.

Why would someone still compound progesterone? Three scenarios:

1. Peanut allergy: Prometrium capsules contain peanut oil. Compounded alternatives use olive oil or other vehicles.
2. Topical or vaginal delivery: no FDA-approved progesterone cream exists for systemic absorption, though evidence for transdermal progesterone achieving adequate serum levels remains mixed [10].
3. Sustained-release formulations: some prescribers prefer slow-release oral progesterone for patients who experience drowsiness with immediate-release dosing.

If none of these apply, generic micronized progesterone offers equivalent clinical outcomes at lower cost with guaranteed potency.

Testosterone for Women: Where Compounding Remains Necessary

No FDA-approved testosterone product for women exists in the United States. The Global Consensus Position Statement on testosterone therapy for women (2019) recommended testosterone for hypoactive sexual desire disorder (HSDD) in postmenopausal women, noting that off-label use of male formulations requires dose adjustment [11]. The Australian ADORE trial and the European INTIMATE trials established efficacy at doses producing physiologic female testosterone levels (typically 5 to 10 mg/day transdermal) [12].

Compounding is the standard pathway for female testosterone therapy. WIP, Belmar, Help, and other accredited pharmacies all produce testosterone creams at 0.5 to 2 mg/day dosing. The choice between pharmacies for this indication comes down to:

• Vehicle preference (cream vs. gel vs. troche)
• Pricing (typically $30, $60/month compounded)
• Whether your prescriber has an existing relationship with the pharmacy

One emerging alternative: commercially available 1% testosterone gel (AndroGel, Testim) prescribed at one-tenth the male dose. This approach avoids compounding entirely but requires careful dose titration and lacks female-specific pharmacokinetic validation.

Thyroid Compounding: WIP vs. Alternatives

WIP compounds desiccated thyroid, sustained-release T3, and combination T3/T4 capsules. For patients who prefer compounded thyroid, the relevant comparison is:

• WIP vs. commercial desiccated thyroid (Armour Thyroid, NP Thyroid, WP Thyroid): commercially available products have known potency issues. The FDA issued recalls for NP Thyroid in 2020 due to sub-potent batches [13]. Armour Thyroid has experienced supply disruptions.
• WIP vs. other compounders for sustained-release T3: College Pharmacy and Belmar both compound SR liothyronine. Pricing is comparable ($25, $50/month).

The 2014 American Thyroid Association guidelines acknowledge that combination T3/T4 therapy may benefit a subset of hypothyroid patients who remain symptomatic on levothyroxine alone, though they do not endorse routine use [14].

Cost Comparison Framework

Pricing varies by formulation, dose, and quantity. Representative monthly costs:

| Formulation | WIP (est.) | Belmar (est.) | Help (est.) | FDA-approved generic | |---|---|---|---|---| | Estradiol cream | $40, $70 | $35, $65 | $30, $55 | $25, $50 (patch) | | Progesterone capsule | $30, $50 | $30, $45 | $25, $40 | $15, $40 (Prometrium generic) | | Testosterone cream (female dose) | $35, $60 | $30, $55 | $25, $50 | N/A | | Combination Biest + Progesterone | $60, $100 | $55, $90 | $50, $85 | N/A |

Insurance rarely covers compounded hormones. Some HSA/FSA accounts reimburse with a valid prescription. FDA-approved alternatives are more likely to receive insurance coverage, though prior authorization requirements vary by plan.

How to Evaluate Whether to Switch

Five clinical questions to discuss with your prescriber:

1. Can your current regimen be replicated with FDA-approved products?
2. Are you using a formulation that only compounding can provide (combination Biest, SR progesterone, female testosterone)?
3. Is your current pharmacy PCAB-accredited or 503B-registered?
4. Have you experienced inconsistency between refill batches?
5. Would telehealth integration reduce friction in your refill and monitoring workflow?

If questions 1 and 3 both return "yes" and question 2 returns "no," an FDA-approved alternative likely offers equivalent outcomes with better regulatory guarantees. If question 2 returns "yes," staying with a compounding pharmacy (whether WIP or an alternative) remains the appropriate path.

Safety Considerations for All Compounded Hormones

The WHI trial (N=16,608 for E+P arm) established that combination estrogen-progestin therapy carries breast cancer, stroke, and VTE risks that apply regardless of whether the hormones are compounded or manufactured [15]. The KEEPS trial (N=727) and the Danish Osteoporosis Prevention Study (N=1,006) provided reassurance that early initiation (within 6 years of menopause) with lower doses carries a more favorable risk profile [16].

"There is no evidence that compounded bioidentical hormones are safer than FDA-approved hormones," stated the Endocrine Society in their 2016 position statement. "The benefits and risks are expected to be the same for the same hormones, doses, and routes of administration" [3].

This means the decision between WIP and alternatives should be based on formulation availability, cost, convenience, and quality assurance rather than a belief that compounded equals safer.

The 503B Advantage: Help and Similar Facilities

Help Pharmacy operates as a 503B outsourcing facility, which means:

• FDA registers and inspects the facility
• Products undergo batch potency and sterility testing
• Adverse event reporting to MedWatch is mandatory
• Beyond-use dating is supported by stability studies

For patients who value compounding flexibility but want closer-to-pharmaceutical regulatory oversight, a 503B facility occupies a middle position between traditional compounders (like WIP) and commercial manufacturers. The trade-off: 503B facilities may offer a narrower formulary than 503A pharmacies because FDA oversight requires more extensive documentation for each product.